These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6138 related articles for article (PubMed ID: 2233614)

  • 1. [Immunotoxin: from the idea of "magic bullets" to clinical applications].
    Engert A; Thorpe P
    Med Klin (Munich); 1990 Sep; 85(9):555-60. PubMed ID: 2233614
    [No Abstract]   [Full Text] [Related]  

  • 2. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
    Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
    Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotoxin therapy of hematological malignancies.
    Pasqualucci L; Flenghi L; Terenzi A; Bolognesi A; Stirpe F; Bigerna B; Falini B
    Haematologica; 1995; 80(6):546-56. PubMed ID: 8647523
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
    Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
    J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody-mediated targeting of alkylating agents for the treatment of cancer.
    Smyth MJ; Pietersz GA; Farquhar I; McKenzie C
    Targeted Diagn Ther; 1988; 1():123-56. PubMed ID: 2979055
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotoxins: magic bullets or misguided missiles?
    Vitetta ES; Thorpe PE; Uhr JW
    Immunol Today; 1993 Jun; 14(6):252-9. PubMed ID: 8397766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
    Fulton RJ; Uhr JW; Vitetta ES
    J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of monoclonal antibodies in the immunotherapy of neoplasms].
    Robak T
    Przegl Lek; 1989; 46(4):420-6. PubMed ID: 2672121
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.
    Bera TK; Viner J; Brinkmann E; Pastan I
    Cancer Res; 1999 Aug; 59(16):4018-22. PubMed ID: 10463601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.
    Byers VS; Pimm MV; Scannon PJ; Pawluczyk I; Baldwin RW
    Cancer Res; 1987 Oct; 47(19):5042-6. PubMed ID: 3497715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of hyperthermia on the immunological system with regard to antineoplastic immunity].
    Roszkowski W
    Postepy Hig Med Dosw; 1981; 35(5):451-70. PubMed ID: 6752919
    [No Abstract]   [Full Text] [Related]  

  • 13. Synthesis and testing of antibody-antifolate conjugates for drug targeting.
    Ghose T; Blair AH; Kralovec J; Mammen M; Uadia PO
    Targeted Diagn Ther; 1988; 1():81-122. PubMed ID: 2979064
    [No Abstract]   [Full Text] [Related]  

  • 14. Rapid screening with indirect immunotoxin for monoclonal antibodies against human small cell lung cancer.
    Weltman JK; Pedroso P; Johnson SA; Davignon D; Fast LD; Leone LA
    Cancer Res; 1987 Nov; 47(21):5552-6. PubMed ID: 2822229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in immunotoxin biology and therapy: a summary of the Fourth International Symposium on Immunotoxins.
    Frankel AE; FitzGerald D; Siegall C; Press OW
    Cancer Res; 1996 Feb; 56(4):926-32. PubMed ID: 8631036
    [No Abstract]   [Full Text] [Related]  

  • 16. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
    Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ
    J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouse multivalent IgG(2a, b) antibody--ricin A-chain immunotoxins combined with homologous or heterologous interleukin 2 in the treatment of a murine malignant lymphoproliferation (EL4).
    Mota G; Marches R; Cialacu V; Roman V; Kozma E; Mărgineanu M; Dima S; Moraru II
    Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):131-6. PubMed ID: 8915518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapy.
    Schwartz MA; Scheinberg DA; Houghton AN
    Cancer Chemother Biol Response Modif; 1992; 13():156-74. PubMed ID: 1389908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 307.